NCT06065280Completed
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in HFrEF Patients
Sodium-glucose Transport 2 Inhibitors (SGLT2i) in Heart Failure Reduced Ejection Fraction (HFrEF) Patients
Source: ClinicalTrials.gov · Last updated 4 Feb 2025
Brief summary (registry, in English)
The aim of this study is to assess the efficacy, safety and cardiovascular outcomes of Sodium-glucose transport protein 2 inhibitors (SGLT2i) therapy in patients with heart failure reduced ejection fraction ( HFrEF) with and without diabetes mellitus and is to evaluate short-term effect of these drugs using the cardiac biomarkers Neopterin.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 80 (actual)
- First submitted
- 27 Sept 2023
- Start date
- 1 Nov 2022
- Primary completion date
- 1 Dec 2024
- Lead sponsor
- Damanhour University
- Diseases
- Heart failure
- NCT number
- NCT06065280
What you commit to
- Study type: Interventional
- Participants enrolled: 80
- From 1 Nov 2022 to the primary completion date, 1 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Recent treatment with or unacceptable side effects associated with an SGLT2i
Other illness
- Type-I diabetes mellitus,
Lab values
- Severe CKD and an estimated glomerular filtration rate (eGFR) below 30 ml per minute per 1.73 m2 of body-surface area or rapidly declining renal function
Other
- Symptoms of hypotension or a systolic blood pressure of less than 95 mm Hg,
- Inability to give informed consent
Who the study is looking for
- Patients with HFrEF, on optimal medical therapy according to European Society of Cardiology guidelines,
- an age of at least 18 years,
- an ejection fraction of 40% or less, with New York Heart Association (NYHA) class II - IV symptoms will be eligible for the study.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Damanhour Teaching Hospital, General Organization for Teaching Hospitals and Institutes. Coordinator of this site? Confirm its status | Damanhūr | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.